| Status ▲ | Population | Trial_Name | Description | Phase | Centers | PI | IIST_Pharma |
| PENDING | MPNST, LMS, ESS | Phase Ib of Metronomic Selinexor in MPNST, LMS and ESS | METSSAR-1
| Ib/II | PMH | A. Razak | IIST |
| PENDING | Any soft tissue sarcoma undergoing surgery and radiation | Circulating Tumor DNA in Soft Tissue Sarcoma | Liquid biopsy in early disease for soft tissue sarcoma | Proof of Concept | PMH | A. Razak
D. Shultz | IIST |
| PENDING | PVNS/TGCT | A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor | Emactuzumab vs. placebo | III | TBD | A. Razak | Pharma |
| PENDING | Various STS subtypes | BRIGHTLINE-3 | MDM2i + CPI in selected sarcomas, TP53 WT | III | TBD | A. Razak | |
| PENDING | Osteosarcoma (AYA -residual OST (up to 30 yrs) | CLIN-60000-461: A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment | Cabozantinib + best supportive care vs best supportive care only | II | TBD | A. Gupta | Pharma |
| PENDING | All sarcoma - initial consult | Evaluating the Use of Educational Videos in a Medical Oncology Sarcoma Clinic to Improve Patient Knowledge and Satisfaction | Early intervention palliative care vs SOC | Pilot | MSH and PMH only | A. Razak | IIST |
| RECRUITING | Localized high risk sarcoma | Prospective Study of Hypoxia Imaging in Patients with Soft Tissue Sarcoma using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA) in combination with MRI | FAZA for STS
| Proof of Concept | PMH | D. Shultz | IIST |
| RECRUITING | resectable LMS, LPS | SR.7/1809-STBSG/STRASS-2. A Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk Retroperitoneal Sarcoma | Surgery vs. Surgery plus Chemo
| III | PMH
MSH | R. Gladdy | NCIC/EORTC |
| RECRUITING | Relapsed Osteosarcoma (1-35yrs) | PED-CITN-03: Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma | Biological: Dinutuximab, Magrolimab | I | SickKids, BCCH | D. Morgenstern, R. Deyell | NCI |
| RECRUITING | Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma + other (2 -25yrs) | DCL-17-001: An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors | Drug: CLR 131 | I | SickKids | D. Morgenstern | Pharma |
| RECRUITING | Ewing Sarcoma, Rhabdomyosarcoma, other Solid Tumors (2-20yrs) | ADVL1921: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE(REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE AND/OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS | Palbociclib + chemo | II | SickKids
CHU Ste-Justine | D. Morgernstern
Y. Samson | COG + Pharma |
| RECRUITING | GIST | (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORS | Sunitinib +/- CGT9486 | III | PMH | A. Razak | Pharma |
| RECRUITING | GIST | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT) | Ripretinib vs sunitinib | III | PMH | A. Razak | Pharma |
| RECRUITING | LMS | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | ADI-PEG 20 (arginine degrading enzyme) or Placebo Plus Gemcitabine and Docetaxel | III | TBD | A. Razak | Pharma |
| RECRUITING | Chondrosarcoma | A phase 3, multicenter, double blind, randomized, placebo-controlled study of ivosidenib in subjects ≥ 18 years of age with unresectable or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 prior systemic treatment regimen | Ivosidenib vs. placebo | III | TBD | A. Salawu | Pharma |
| RECRUITING | Synovial Sarcoma | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | Adoptive cell therapy (ACT) in Synovial Sarcoma and m-Liposarcoma | II | PMH | A. Razak | Pharma |
| RECRUITING | Relapsed/Refractory Solid Tumours | 23ME-00610-CLIN-001 | 23ME-00610 given by intravenous infusion | I/II | SickKids | D. Morgenstern | Pharma |
| RECRUITING | Advanced Solid Tumour/LGG, Age ≥12 years | DAY101-102 | Tovorafenib, Tovorafenib plus pimasertib | | SickKids | D. Morgenstern | Pharma |
| RECRUITING | Recurrent/Refractory Ewing Sarcoma, Hepatoblastoma, Neuroblastoma, Osteosarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Wilms, Sarcoma | ONITT | Onivyde With Talazoparib or Temozolomide | I | SickKids, BCCH | D. Morgenstern, R. Deyell | IIST |
| RECRUITING | Relapsed or refractory Solid tumors, lymphoma, brain tumors | BMS BET 19-040 | investigational drug called BMS-986158 | I | SickKids | D. Morgenstern | IIST |
| RECRUITING | R/R solid tumor, including CNS tumors, with a mutation in PDGFRA and/or KIT. 2-18 yrs | BLU-285-3101 | This is a Phase 1/2, multicenter, open-label trial of avapritinib, | I/II | SickKids | D. Morgenstern | Pharma |
| RECRUITING | Advanced and unresectable or metastatic solid malignancy | BO41932 (TAPISTRY). unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay | Targeted therapies or immunotherapy as single agents or in rational, specified combinations. | II | SickKids | D. Morgenstern | Pharma |
| RECRUITING | Advanced Solid Tumor | RP-6306 | RP-6306 alone and in combination with RP-3500
| I | SickKids | D. Morgenstern | Pharma |
| RECRUITING | DDLPS any line | Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma | MDM2i | Drug access trial | TBD | A. Razak | Pharma |
| RECRUITING | All sarcoma | SARQUALITY: Integrating early palliative care in advanced SARcoma patients for enhanced QUALITY of life. | Patient education videos vs SOC | Pilot | MSH and PMH only | A. Razak | IIST |
| CLOSED | Synovial Sarcoma | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | ACT in SS
| II | PMH
HMR | A. Razak
J. Noujaim | Pharma |
| CLOSED | LMS | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) | DAPPER Study
| II | PMH | L.Siu
A. Razak | IIST |
| CLOSED | Extremity/ trunk STS | Phase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue Sarcoma | Pre vs Postop IMRT in extremity STS (50/50 study)
| III | PMH
MSH
HMR
OHRI
DanaFarber
ClevalandClinic
OHSU
SaintLuc(Brussels) | P. Chung | IIST |
| CLOSED | Osteosarcoma | OLIE | ifosfamide and etoposide with or without Lenvatinib in children, adolescents and young adults | I | SickKids | D. Morgenstern | Pharma |
| CLOSED | dd-Liposarcoma, at least 1 prior anthracycline-based regimen | A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma (RAIN-3201) | Milademetan vs trabectedin
| III | PMH | A. Razak | Pharma (***Patient Reimbursement) |
| CLOSED | Dedifferentiated liposarcoma | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | I 907828 vs doxorubicin as first line therapy in DDLPS | II/III | PMH, HMR, BCC | A. Razak, J. Noujaim, A. Smrke | Pharma |
| CLOSED | High grade soft tissue sarcoma | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients with Select Solid Tumors (FRONTIER) | FAPi radioligand in high grade soft tissue sarcoma | I | PMH | A. Razak | Pharma |
| CLOSED | LMS (fever than 4 lines of prior treatment) | A Phase II/III Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma (SUNRISE LMS) | DTIC + unesbulin/placebo | II/III | PMH | A. Salawu | Pharma |
| CLOSED | PVNS/TCGT | A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor | ABSK021 (CSF-1R) vs. placebo | III | TBD | A. Razak | Pharma |